American Taiwan Biopharm


American Taiwan Biopharm
Concise Prescribing Info
Doxorubicin HCl (pegylated lipos doxorubicin)
Treatment of refractory & recurrent ovarian cancer. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts & extensive mucocutaneous or visceral disease, metastatic breast cancer. In combination w/ bortezomib for refractory & relapsed multiple myeloma.
Dosage/Direction for Use
Refractory & recurrent ovarian cancer, metastatic breast cancer Monotherapy: 50 mg/m2 by IV infusion over 60 min every 4 wk. In combination: 30-40 mg/m2 IV every 4 wk. AIDS-related KS 20 mg/m2 by IV infusion over 60 min every 2-3 wk. Refractory & relapsed multiple myeloma 30 mg/m2 IV on day 4 in combination w/ bortezomib every 3 wk.
Pregnancy & lactation. AIDS-related KS patients effectively treated w/ local or systemic α-interferon.
Special Precautions
Monitor cardiac function. History of CV disease. Perform blood cell counts during therapy. Diabetics. May impair ability to drive or operate machinery.
Adverse Reactions
Hematologic disorders, palmar-plantar erythrodysesthesia, stomatitis, asthenia, rash, GI disturbances, alopecia, anorexia, mucosal membrane disorder, fever, paresthesia, pain, skin discoloration, pharyngitis, dry skin, somnolence. Infusion-related reactions.
Drug Interactions
Elevates cyclophosphamide-induced bleeding cystitis & hepatic toxicity of 6-mercaptopurine. Other anticancer drugs that may induce bone marrow suppression.
ATC Classification
L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Lipo-Dox infusion 2 mg/mL
10 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in